Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant for CINV in Pediatric Cancer
NCT05230654Unknown
- Start
- Feb 2022
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing Fosaprepitant Group with Placebo Group (2 arms). Primary endpoint: Complete Remission Rate in the Delayed Period. Status: unknown.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT05230654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230654.